SLC5A2 and chronic kidney disease: Taken together, in the subgroup of participants with T2D and established CKD, there was a slowing in the rate of decline of kidney function and a reduced incidence of dialysis, transplantation or death due to kidney disease (relative risk (RR) 0.67; 95% CI 0.52–0.86, P = 0.0019) in participants receiving an SGLT2 inhibitor (55, 56).